<DOC>
	<DOC>NCT02004379</DOC>
	<brief_summary>Know through routine clinical practice the effectiveness and safety of current treatment of hepatitis C virus, genotype 1, for patients who have never been treated and for patients who have been previously treated</brief_summary>
	<brief_title>Register of Telaprevir and Boceprevir in Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Patients infected by hepatitis C virus, genotype 1 Indication of treatment with telaprevir or boceprevir in F3 and F4 fibrosis Being taking part in other Inability to follow a monitoring Contraindications on triple therapy Coinfected with HIV and HBV (hepatitis B virus)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>telaprevir</keyword>
	<keyword>boceprevir</keyword>
	<keyword>clinical practice</keyword>
</DOC>